# FDC, FDCA, & Amendments

## Pure Food & Drug Act (1906)

`Foundations of the FDA`

- **Upton Sinclair's The Jungle**: exposed unsanitary practices in the meatpacking industry; enacted in response.
- **Purity Standards**: defined drugs based on the standards of the United States Pharmacopoeia and the National Formulary (USP-NF).
- **Prohibitions on the Sale of Misbranded or Adultered Food & Drugs in Interstate Commerce**: products cannot be falsely labeled, and their ingredients could not be adulterated or substituted.
  - `Adulteration`: Contanimation or failure to meet purity & quality standards.
  - `Misbranding`: Including false, inaccurate, improper, or confusing labeling or if the product is harmful when used according to label directions.
- **Labeling Requirements**: mandates truthfulness & disclosure of the presence and amount of dangerous ingredients
- **Origins of the FDA**: This act was enforced by the Bureau of Chemistry until the Food, Drug, & Insecticide Administration was formed in 1927 and rebranded as the FDA in 1930.

## Food, Drug, & Cosmetic Act (FDCA, 1938)

`Drugs must be proven SAFE & require PREMARKET APPROVAL`

- **Sulfanilamide Tragedy**: a mass poisoning incident involving elixir sulfanilamide, which killed over 100 people; enacted in response.
  - ðŸ¤¯ Sulfanilamide is now FDA-approved for treating vaginal yeast infections.
- **Premarket Approval**: established the principle that new drugs must be reviewed and approved by the FDA before they can be marketed and sold to the public.
  - **Safety Testing**: requires manufacturers to demonstrate that new drugs were safe for use under prescribed conditions on their labels.
  - **Marketing & Labeling**: requires labels to have warnings about habit formation, provide adequate directions for use, and warn against unsafe use.
- **FDC Coverage Expansion**: include medical devices and cosmetics, which were previously unregulated.
- **Enforcement Tools**
  - **Injunctions**: allows the FDA to file injunctions to `recall` & seize products.
  - **Factory Inspections**: gives the FDA the authority to inspect factories to ensure adherence to manufacturing, processing, packaging, & storage standards.

## Durham-Humphrey Amendment (1951)

- **Restrictions on Access**: explicitly defined prescription (Rx) and over-the-counter (OTC) drugs, separating them based on safety and the need for medical supervision.
  - **OTC Drugs**: Medications that may be sold without a prescription as long as they are appropriately labeled for home use.
  - **Rx Drugs**: Medications that may not be dispensed to the public except on the order or *prescription* of a licensed prescriber.
  - **Medication Orders**: a written request on a physician's order form OR a transcribed verbal/ telephone order in an *inpatient* setting.
  - **Prescriptions**: medication order on a prescription blank to be filled in an *outpatient/ ambulatory* setting.
- **Verbal Prescriptions**: Legalized the transmission of prescriptions via telephone.
- **Refills**: Allows pharmacists to refill prescriptions as indicated by the prescribing physician.
- **Legend Label**: Rx drugs were required to carry a label stating, "Caution: Federal law prohibits dispensing without a prescription" or "RX Only".

## Kefauver-Harris Amendment (1962)

`Drugs must also be proven EFFECTIVE for their intended use`

- **Thalidomide Tragedy**: a drug used to treat morning sickness in pregnant women caused severe birth defects in children; enacted in response.
  - ðŸ¤¯ Thalidomide is now FDA-approved for treating multiple myeloma and leprosy. Use requires strict risk acknowledgment from both men and women.
- **Pre-Marketing Approval**: requires pre-marketing approval from the FDA before a drug could be marketed; must be proven **effective**
- **Good Manufacturing Practices (GMP)**: formalizes guidelines for how drugs are manufactured, processed, packaged, and held to ensure they meet quality standards.
- **Adverse Event Reporting**: requires that adverse events reported during clinical trials be reported to the FDA.

## ðŸ¤¯ Medical Device Amendments (1951)

- **Dalkon Shield Disaster**: an intrauterine device (IUD) caused significant harm & death to users due to faulty design; enacted in response.
- **Medical Device Classification**: requires that all medical devices be classified into one of three classes:
  - Class I (General Controls): devices deemed low-risk for human use.
  - Class II (Performance Standards): devices considered moderate-risk for human use.
  - Class III (**Premarket Approval**): devices deemed high-risk for human use (e.g. life-support systems).

## ðŸ¤¯ Orphan Drug Act (1983)

- **Orphan Drug Designation**: defined as drugs intended to treat a rare disease or condition, or if there's no reasonable expectation that the drug's development costs will be recovered through sales.
- **Incentives for Development**
  - **Tax Credits**: A 25% tax credit for clinical trials of orphan drug
  - **Extended Market Exclusivity**: A seven-year period of exclusive marketing rights.
  - **Federal Funding & Grants**
  - **User Fee Waiver**

## ðŸ¤¯ Drug Price Competition & Patent Term Restoration Act (Hatch-Waxman, 1984)

- **Abbreviated New Drug Application (ANDA) Process**: allows generic drug manufacturers to seek approval by demonstrating that their drug is bioequivalent (i.e., has the same effect) to a brand-name drug already on the market.
- **Patent Term Extension**: provides for patent term extensions for brand-name drugs, which can add up to five years to the patent's life.
- **Patent Litigation**: established a process for patent litigation between brand-name and generic drug manufacturers.
- **Exclusivity Periods**: generic drug manufacturers cannot file an ANDA for a certain period after the brand-name drug's approval.

## Prescription Drug Marketing Act (PDMA, 1987)

- **Bans Reimportation**: restricts the reimportation of prescription drugs manufactured in the US, **except by the manufacturer**; preventing the entry of potentially compromised or counterfeit drugs.
- **Drug Sample Distribution**: Only **Wholesalers & Manufacturers** may provide medication samples to licensed prescribers upon request and with proper record-keeping; preventing the illegal sale of samples.
- **Wholesale Distributor Licensing**: Wholesalers must be licensed by the state they operate in and meet uniform standards.

## ðŸ¤¯ Food & Drug Administration Amendments Act (FDAAA, 2007)

- **Clinical Trial Registration & Reporting**: mandates that clinical trials registered & reported to the FDA; applies to most, with some exceptions for phase I studies.
- **Pediatric Clinical Trial Requirements**: requirement for pediatric labeling changes, priority review recommendations, and deferred studies (i.e. after adult trials).
- Grants the FDA the authority to implement **Risk Evaluation & Mitigation Strategies (REMS)** to manage risks associated with prescription drugs; particularly those that are addictive (e.g. Opioids, Stimulants, Benzodiazepines), hazardous (e.g. Birth Control, Oncologics, Biologics), or understudied (e.g. Gabapentin). Depending on the drug, a REMS program may include one or more of the following:
  - Mandated **Medication guides** or **patient package inserts (PPIs)**
  - Prescriber training and certification requirements
  - Pharmacy certification and restricted dispensing systems
  - Enrollment of patients in registries or special monitoring programs

## ðŸ¤¯ Drug Quality & Security Act (2013)

`Expands FDA authority to compounded drugs`

- **"Outsourcing Facility" Designation**: Allows pharmaceutical compounders to voluntarily register with the FDA as an outsourcing facility.
- **cGMP Compliance**: Outsourcing facilities must adhere to current Good Manufacturing Practices (cGMP).
- **Exemptions**: Outsourcing facilities may be exempt from certain new drug requirements and labeling requirements, but must still adhere to cGMP.
- **Reporting Requirements**: Outsourcing facilities must report biannually on the drugs they compound and submit adverse event reports.
- **Risk-Based Inspections**: Outsourcing facilities are subject to a risk-based inspection schedule.
  
---

ðŸ”™ðŸ”— Back to [**Federal Law Reference Directory**](./readme.md)
